Lancet Diabetes Endocrinol
Can once-weekly semaglutide reverse prediabetes?
Semaglutide 2.4 mg is more effective than placebo at reducing weight and achieving normoglycaemia. These findings suggest that semaglutide 2.4 mg could be a promising treatment to reverse prediabetes in individuals with obesity.
- The phase 3 STEP 10 trial investigated the efficacy and safety of semaglutide 2.4 mg over one year in 181 adults with obesity and prediabetes. Participants were randomly assigned (2:1) to once-weekly SC semaglutide 2.4 mg (n=138) or placebo (n=69) with diet and physical activity counselling for one year, followed by a 28-week off-treatment period. Most participants were female (71%) and White (88%). Primary outcomes measured were change in body weight and reversion to normoglycaemia.
- At 52 weeks, the semaglutide 2.4 mg group saw a 13.9% decrease in body weight vs. 2.7% in the placebo group. In addition, the majority of participants in the semaglutide 2.4 mg group reverted to normoglycemia by week 52 compared with the placebo group (81% vs. 14%).
- Rates of adverse events leading to treatment discontinuation were 6% in the semaglutide 2.4 mg group vs. 1% in the placebo group. No new safety signals were detected.
Source:
McGowan BM, et al; STEP 10 Study Group. (2024, July 29). Lancet Diabetes Endocrinol. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/39089293/